Immunological analysis of human immunodeficiency virus type 1 envelope glycoprotein proteolytic cleavage.
Two potential cleavage sites have been identified on precursor gp 160 of human immunodeficiency virus type 1. Using antibodies directed against the C-terminus of gp 120, including the sequence between the two sites, we have shown that nonmutated viral and recombinant gp 160 are cleaved at both sites: the great majority of molecules are cleaved at site 1 (Arg-Glu-Lys-Arg), and gp41 can then associate as an oligomer; a minority of molecules are cleaved at site 2 (Lys-Ala-Lys-Arg-Arg) and the corresponding gp41 appears to present as a monomer. This could reflect two different processing pathways for gp41 biosynthesis, one of which only may result in biologically active molecules according to the literature.
Fenouillet
E
E
Laboratoire de Biologie et Génétique des Pathologies Immunitaires, CNRS URA 1463, CERVI, Hôpital de la Pitié-Salpêtrière, Paris, France.
Gluckman
J C
JC
D000595:Amino Acid Sequence; D010450:Endopeptidases / Q000378:metabolism; D000939:Epitopes; D015686:Gene Products, env / Q000276:immunology / Q000378:metabolism*; D015699:HIV Envelope Protein gp120 / Q000276:immunology / Q000378:metabolism; D019302:HIV Envelope Protein gp160; D015700:HIV Envelope Protein gp41 / Q000276:immunology / Q000378:metabolism; D015497:HIV-1 / Q000276:immunology / Q000378:metabolism*; D008969:Molecular Sequence Data; D011498:Protein Precursors / Q000276:immunology / Q000378:metabolism*; D011499:Protein Processing, Post-Translational
D000939:Epitopes; D015686:Gene Products, env; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D015700:HIV Envelope Protein gp41; D011498:Protein Precursors; D010450:Endopeptidases